Table 3.
Pathology specimen findings in randomized trials of neoadjuvant androgen deprivation therapy and radical prostatectomy versus immediate radical prostatectomy alone for clinically localized prostate cancer
| Author | Year | n | Clinical Stage | Neoadjuvant therapy | Therapy duration | Clinical downstaging (%) | Pathological downstaging (%) | Organ confined (%) | Positive margins (%) | Seminal vesicle invasion (%) | pN+ (%) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Labrie et al.[46] | 1993 | 142 | B0-C2 | Leuprolide, Flutamide | 3 months | Neo 43, RP 8 | Neo 77, RP 34 | Neo 13, RP 39 | Neo 12, RP 34 | Neo 3, RP 6 | |
| Debruyne et al.[47] | 1994 | 125 | T2-3N0M0 | Goserelin, Flutamide | 3 months | Neo 34 | Neo 19, RP 8 | Neo 27, RP 39 | |||
| Soloway et al.[48] | 1995 | 303 | T2bNxM0 | Leuprolide, Flutamide | 3 months | Neo 53, RP 22 | Neo 18, RP 48 | Neo 15, RP 22 | Neo 6, RP 6 | ||
| Van Poppel et al.[49] | 1995 | 130 | T2b-T3 | Estramustine Phosphate~ | 1.5 months | Neo 22 | Neo 26, RP 23 | Neo 72, RP 63 | Neo 32/31/19^, RP 44/27/10^ | ||
| Dalkin et al.[50] | 1996 | 56 | T1c-T2b | Goserelin | 3 months | Neo 57, RP 61 | Neo 4, RP 4 | ||||
| Goldenberg et al.[51] | 1996 | 213 | T1b-T2c | Cyproterone | 3 months | Neo 42, RP 20 | Neo 28, RP 65 | Neo 28, RP 14 | Neo 7, RP 3 | ||
| Hugosson et al.[52] | 1996 | 111 | T1b-3aN0M0 | Triptorelin, Cyproterone | 3 months | Neo 23, RP 41 | |||||
| Witjes et al.[53] | 1997 | 354 | T2-3N0M0 | Goserelin, Flutamide | 3 months | Neo 32 | Neo 16, RP 6 | Neo 45, RP 21 | Neo 27, RP 46 | Neo 13, RP 23 | |
| Aus et al.[54] | 1998 | 122 | T1b-3aNxM0 | Triptorelin, Cyproterone | 3 months | Neo 24, RP 46 | Neo 15, RP 22 | Neo 5, RP 14 | |||
| Fair et al.[55] | 1999 | 140 | T1-T2 | Goserelin, Flutamide | 3 months | Neo 70, RP 59 | Neo 19, RP 37 | ||||
| Schulman et al.*[56] | 2000 | 402 | T2-3N0M0 | Goserelin, Flutamide | 3 months | Neo 30 | Neo 15, RP 7 | Neo 45, RP 24 | Neo 26, RP 48 | Neo 15, RP 23 | |
| Selli et al.[57] | 2002 | 393 | T2-3N0M0 | Goserelin, Bicalutamide | 3/6 months | Neo 49/64, RP 34 | Neo 28/23, RP 53 | Neo 11/11, RP 11 | Neo 8/4, RP 12 | ||
| Soloway et al.*[58] | 2002 | 303 | T2bNxM0 | Leuprolide, Flutamide | 3 months | Neo 18, RP 48 | Neo 15, RP 22 | Neo 6, RP 6 | |||
| Prezioso et al.[59] | 2004 | 183 | T1a-2bN0M0 | Leuprolide, Cyproterone | 3 months | Neo 39, RP 60 | Neo 3, RP 11 | ||||
| Gravina et al.[60] | 2007 | 430 | T2-T3a | Bicalutamide | 4 months | Neo 13, RP 35 | |||||
| Yee et al.*[61] | 2010 | 148 | T1b-T3 | Goserelin, Flutamide | 3 months | Neo 85, RP 80 | Neo 19, RP 38 | Neo 4, RP 6 | Neo 1, RP 3 |
*Follow-up report of prior study, ~Cytotoxic agent, not truly ADT, ^Margins reported as posterolateral, apical, base margins. pN+=Pathological lymph node positive status, Neo=Neoadjuvant androgen deprivation therapy, RP=Radical prostatectomy